FDA Approves First Treatment Targeting the Root Cause of Rare Alexander Disease

The U.S. Food and Drug Administration has approved Zanvastro, the first medication designed to directly target Alexander disease, a rare and often fatal neurological disorder. The treatment represents a major development for patients who previously had access only to supportive care aimed at managing symptoms.

Alexander disease progressively damages the brain and spinal cord, affecting movement, cognitive abilities and essential automatic functions such as breathing and heart rate. By targeting an underlying cause of the condition, Zanvastro is considered a disease-modifying therapy rather than a treatment focused solely on symptom relief.

Understanding Alexander disease

Alexander disease affects fewer than one in 1 million people worldwide, but its consequences for patients and their families can be severe. Symptoms may include seizures, developmental regression, muscle stiffness, difficulty walking and progressively worsening problems with speech or swallowing.

The disorder can develop during infancy, childhood or adulthood, with its progression varying according to the age of onset. Younger patients frequently experience more severe and rapidly progressing forms, while some adults undergo a slower decline. These differences can make diagnosis difficult without genetic testing.

For decades, treatment options were limited to rehabilitation, medications for seizures or muscle spasticity, and other supportive interventions. No approved medication could modify the underlying disease process or slow the progressive accumulation of neurological damage.

Genetic discovery opened the door

The scientific journey toward Zanvastro began in the late 1990s, when researchers identified mutations in the GFAP gene as the cause of Alexander disease. This gene produces glial fibrillary acidic protein, a structural protein found in astrocytes, specialized support cells that help maintain normal brain function.

Researchers at the University of Wisconsin–Madison and the University of Alabama at Birmingham developed genetically modified mice that produced excessive amounts of GFAP, initially intending to investigate astrocyte biology. Unexpectedly, the animals developed abnormal protein deposits within their astrocytes that closely resembled those observed in people with Alexander disease.

Known as Rosenthal fibers, these deposits became a defining feature of the disorder and provided evidence that excessive or abnormal GFAP plays a central role in its development. The discovery clarified the disease's biological mechanisms and transformed diagnosis by making blood-based genetic testing possible instead of invasive brain biopsies.

How Zanvastro works in the brain

After establishing the importance of GFAP in Alexander disease, scientists began investigating methods to reduce its production in affected brain cells. Researchers at Wisconsin's Waisman Center developed improved rodent models that reproduced important characteristics of the human disorder.

In collaboration with Ionis Pharmaceuticals, the researchers explored antisense oligonucleotides, short synthetic strands of genetic material designed to selectively interfere with the instructions used to produce a particular protein. Their objective was to lower GFAP production sufficiently to prevent harmful accumulation within astrocytes.

Preclinical experiments involving mice and other models demonstrated that antisense treatment could safely reduce GFAP levels, decrease the formation of Rosenthal fibers and improve neurological function. These encouraging results supported the development of the experimental therapy, subsequently named Zanvastro, for testing in humans.

Clinical trial results and approval

Ionis conducted an international phase 3 clinical trial involving 54 people with Alexander disease across a broad age range. The study took place at 13 research sites, with participants receiving regular injections of Zanvastro or a comparison treatment into the spinal canal over a period slightly longer than one year.

Participants treated with Zanvastro demonstrated significantly better walking speeds than those in the control group. Walking speed was an important measure because mobility typically deteriorates as Alexander disease progresses. The treatment also appeared to stabilize broader motor abilities, slowing or preventing the decline that would otherwise be expected.

Some participants experienced measurable improvements in movement, an outcome rarely observed in progressive neurodegenerative disorders. Safety findings supported continued treatment, contributing to the FDA's decision to approve Zanvastro for patients ranging from infancy through adulthood.

The medication is administered once every three months by a trained healthcare professional through an injection into the spinal canal, allowing it to reach the central nervous system. Availability in the United States is expected within weeks of approval, while Recordati will oversee access in other regions under a licensing agreement.

A model for rare disease research

Zanvastro's approval represents the culmination of more than 30 years of scientific investigation that began with fundamental research into astrocytes. An unexpected observation in genetically engineered mice eventually helped reveal the genetic basis of a rare neurological disease and identify a promising treatment target.

Researchers regard this development as an important example of translational medicine, demonstrating how laboratory discoveries can eventually produce meaningful benefits for patients with conditions that previously lacked disease-modifying treatments. It also illustrates the importance of animal models that accurately reproduce key features of human disease.

Families affected by Alexander disease made essential contributions by providing biological samples, participating in patient registries and enrolling in clinical trials. Researchers emphasize that further studies will be necessary to evaluate long-term treatment outcomes, determine optimal dosing and establish whether starting therapy early can prevent irreversible neurological damage.

The development of Zanvastro may also support efforts to create similar antisense treatments for other rare neurological disorders associated with harmful protein accumulation. For patients and families who have waited decades for a targeted therapy, the approval offers new hope while providing a potential framework for future medical advances.